BR112019012106A2 - inibidores de azepano de interação menin-mill - Google Patents
inibidores de azepano de interação menin-millInfo
- Publication number
- BR112019012106A2 BR112019012106A2 BR112019012106-4A BR112019012106A BR112019012106A2 BR 112019012106 A2 BR112019012106 A2 BR 112019012106A2 BR 112019012106 A BR112019012106 A BR 112019012106A BR 112019012106 A2 BR112019012106 A2 BR 112019012106A2
- Authority
- BR
- Brazil
- Prior art keywords
- azepane
- inhibitors
- menin
- mill
- interaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434549P | 2016-12-15 | 2016-12-15 | |
| EP17150502 | 2017-01-06 | ||
| PCT/EP2017/082826 WO2018109088A1 (en) | 2016-12-15 | 2017-12-14 | Azepane inhibitors of menin-mll interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019012106A2 true BR112019012106A2 (pt) | 2019-10-29 |
Family
ID=60935807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019012106-4A BR112019012106A2 (pt) | 2016-12-15 | 2017-12-14 | inibidores de azepano de interação menin-mill |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10745409B2 (https=) |
| EP (1) | EP3555103B1 (https=) |
| JP (1) | JP7142010B2 (https=) |
| KR (1) | KR102513564B1 (https=) |
| CN (1) | CN110248946B (https=) |
| AU (1) | AU2017376599B2 (https=) |
| BR (1) | BR112019012106A2 (https=) |
| CA (1) | CA3044739A1 (https=) |
| ES (1) | ES2901227T3 (https=) |
| IL (1) | IL267277B (https=) |
| MX (1) | MX391405B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
| CN116693546B (zh) * | 2022-01-28 | 2025-06-27 | 成都先导药物开发股份有限公司 | Menin抑制剂及其用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| JP2005527502A (ja) | 2002-02-19 | 2005-09-15 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ１アデノシン受容体の部分的および全アゴニスト |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| JP4660199B2 (ja) | 2002-12-23 | 2011-03-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| WO2005110410A2 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| EP1856128A4 (en) | 2005-01-19 | 2009-12-23 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
| TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
| WO2010041366A1 (ja) | 2008-10-06 | 2010-04-15 | 日本電気株式会社 | 無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体 |
| JP2011026305A (ja) | 2009-06-24 | 2011-02-10 | Daiichi Sankyo Co Ltd | イミダゾールカルボニル化合物を含有する医薬組成物 |
| CN102984941B (zh) * | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| EP2646455A4 (en) | 2010-12-03 | 2014-04-02 | Epizyme Inc | Modulators of histone methyltransferase, and methods of use thereof |
| US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| CN103228195B (zh) | 2011-08-01 | 2016-01-20 | 奥林巴斯株式会社 | 插入部形状估计装置 |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| CN103664991B (zh) | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| WO2014164543A1 (en) * | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US20170119769A1 (en) * | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016081732A1 (en) * | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| WO2018047598A1 (ja) | 2016-09-06 | 2018-03-15 | 株式会社スリーボンド | 熱硬化型導電性接着剤 |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
-
2017
- 2017-12-14 CN CN201780077761.9A patent/CN110248946B/zh active Active
- 2017-12-14 KR KR1020197019795A patent/KR102513564B1/ko active Active
- 2017-12-14 MX MX2019007067A patent/MX391405B/es unknown
- 2017-12-14 JP JP2019531979A patent/JP7142010B2/ja active Active
- 2017-12-14 US US16/469,174 patent/US10745409B2/en active Active
- 2017-12-14 CA CA3044739A patent/CA3044739A1/en active Pending
- 2017-12-14 ES ES17825447T patent/ES2901227T3/es active Active
- 2017-12-14 BR BR112019012106-4A patent/BR112019012106A2/pt not_active Application Discontinuation
- 2017-12-14 EP EP17825447.0A patent/EP3555103B1/en active Active
- 2017-12-14 AU AU2017376599A patent/AU2017376599B2/en active Active
-
2019
- 2019-06-12 IL IL267277A patent/IL267277B/en unknown
-
2020
- 2020-07-17 US US16/932,070 patent/US11530226B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX391405B (es) | 2025-03-21 |
| CN110248946B (zh) | 2023-05-23 |
| ES2901227T3 (es) | 2022-03-21 |
| JP7142010B2 (ja) | 2022-09-26 |
| AU2017376599A1 (en) | 2019-08-01 |
| EP3555103A1 (en) | 2019-10-23 |
| US20200339594A1 (en) | 2020-10-29 |
| IL267277B (en) | 2022-04-01 |
| CA3044739A1 (en) | 2018-06-21 |
| US20190322685A1 (en) | 2019-10-24 |
| EP3555103B1 (en) | 2021-09-22 |
| KR20190092518A (ko) | 2019-08-07 |
| CN110248946A (zh) | 2019-09-17 |
| US10745409B2 (en) | 2020-08-18 |
| US11530226B2 (en) | 2022-12-20 |
| AU2017376599B2 (en) | 2021-10-07 |
| JP2020512290A (ja) | 2020-04-23 |
| MX2019007067A (es) | 2019-10-15 |
| IL267277A (en) | 2019-08-29 |
| KR102513564B1 (ko) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389598B (es) | Inhibidores bicíclicos condensados de la interacción de menina-mll. | |
| BR112019004691A2 (pt) | inibidores bicíclicos em espiro da interação menina-mll | |
| EA201990699A1 (ru) | Спиробициклические ингибиторы взаимодействия менин–mll | |
| MX2022007652A (es) | Derivados espiráncos sustituidos de cadena lineal. | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| EA201991448A1 (ru) | Азепановые ингибиторы взаимодействия менин-mll | |
| BR112016013861A2 (pt) | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| CR20190394A (es) | Compuestos de inhibidores de autotaxina | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2016007851A (es) | Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| MX2020006594A (es) | Inhibidores de exo-azaespiro de la interaccion menina-mll. | |
| MX377089B (es) | Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral. | |
| BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
| CR20230605A (es) | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos | |
| CL2020003306A1 (es) | Composiciones bifuncionales para el tratamiento del cáncer. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| UY35602A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| MX2017013571A (es) | Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap). | |
| MX2023013174A (es) | Derivados espiro sustituidos. | |
| MX2023013176A (es) | Derivados espiro sustituidos. | |
| BR112016002311A2 (pt) | combinações de inibidor de cinase de pim |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |